CSL (ASX:CSL) warns of delay to Vifor Pharma deal

Company News

by Paul Sanger

Pharma giant CSL has provided an update on its potential acquisition of Swiss group Vifor Pharma. Although the deal was previously expected to close by June 2022, CSL “now expects the regulatory approval process to take a few more months.”

The company did not disclose any impediments to the acquisition.

“CSL remains confident of completing its acquisition of Vifor Pharma AG and looks forward to expanding its presence in the rapidly growing nephrology market, as well as leveraging the companies’ combined expertise to continue to deliver innovative solutions to rare and serious illness,” the company said.

Shares in CSL (ASX:CSL) are trading 2.1 per cent lower at $270.31.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.